99 related articles for article (PubMed ID: 19257969)
1. [Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them].
Cui Y; Zhao JZ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(47):3356-8. PubMed ID: 19257969
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis].
Zhang JM; Sun CY; Yu SZ; Wang Q; An TL; Li YY; Kong YL; Wen YJ
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):454-9. PubMed ID: 22088371
[TBL] [Abstract][Full Text] [Related]
3. The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas.
Sun J; Li DM; Huang J; Liu J; Sun B; Fu DL; Mao GS
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4595-4599. PubMed ID: 29131255
[TBL] [Abstract][Full Text] [Related]
4. Epidermal Growth Factor Receptor and Ki-67 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
Vet Pathol; 2016 Nov; 53(6):1131-1137. PubMed ID: 27154542
[TBL] [Abstract][Full Text] [Related]
5. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype.
Suri VS; Tatke M; Singh D; Sharma A
Indian J Cancer; 2004; 41(2):66-71. PubMed ID: 15318011
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
7. [Changes of folate receptor -α protein expression in human gliomas and its clinical relevance].
Wu H; Zhan Y; Qu Y; Qi X; Li J; Yu C
Zhonghua Wai Ke Za Zhi; 2014 Mar; 52(3):202-7. PubMed ID: 24785460
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma.
Friedrich C; von Bueren AO; Kolevatova L; Bernreuther C; Grob T; Sepulveda-Falla D; van den Boom L; Westphal M; Simon R; Glatzel M
Childs Nerv Syst; 2016 Feb; 32(2):281-90. PubMed ID: 26686534
[TBL] [Abstract][Full Text] [Related]
9. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of cell cycle/apoptosis regulators and epidermal growth factor receptor in pediatric intracranial ependymomas.
Alexiou GA; Stefanaki K; Moschovi M; Patereli A; Prodromou N; Karentzou O
J Child Neurol; 2011 Feb; 26(2):195-8. PubMed ID: 20713981
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome.
Preusser M; Wolfsberger S; Czech T; Slavc I; Budka H; Hainfellner JA
Am J Clin Pathol; 2005 Oct; 124(4):543-9. PubMed ID: 16146813
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
[TBL] [Abstract][Full Text] [Related]
13. The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience.
Ailon T; Dunham C; Carret AS; Tabori U; Mcneely PD; Zelcer S; Wilson B; Lafay-Cousin L; Johnston D; Eisenstat DD; Silva M; Jabado N; Goddard KJ; Fryer C; Hendson G; Hawkins C; Dunn S; Yip S; Singhal A; Hukin J
Childs Nerv Syst; 2015 Jan; 31(1):57-65. PubMed ID: 25391979
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
15. Tumor vessel biology in pediatric intracranial ependymoma.
Wagemakers M; Sie M; Hoving EW; Molema G; de Bont ES; den Dunnen WF
J Neurosurg Pediatr; 2010 Apr; 5(4):335-41. PubMed ID: 20367336
[TBL] [Abstract][Full Text] [Related]
16. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
17. Correlation of p53 and KI-67 expression with grade and subtype of ependymoma.
Manasa LP; Uppin MS; Sundaram C
Indian J Pathol Microbiol; 2012; 55(3):308-13. PubMed ID: 23032822
[TBL] [Abstract][Full Text] [Related]
18. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological evaluation of immunohistochemical Ki-67 and endothelial nitric oxide synthase expression in intracranial ependymoma.
Yan X; Cheng X; Liu J; Luo D; He X; Chen F; Qin C; Wang Y
Clin Invest Med; 2008; 31(4):E206-11. PubMed ID: 18682044
[TBL] [Abstract][Full Text] [Related]
20. Expression of epidermal growth factor receptor and HER-2 in pediatric embryonal brain tumors.
Patereli A; Alexiou GA; Stefanaki K; Moschovi M; Doussis-Anagnostopoulou I; Prodromou N; Karentzou O
Pediatr Neurosurg; 2010; 46(3):188-92. PubMed ID: 20962551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
